A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma
We describe an <i>in vitro</i> test to study the differential response to omalizumab in patients. <i>RSAD2</i> may be a biomarker for response to omalizumab in asthma.
Authors
- Anja Bizjak
- Maja Skerbinjek Kavalar
- Larisa Goričan (ORCID: https://orcid.org/0000-0002-5053-9122)
- M Gorenjak
- M Kabesch
- Susanne J. H. Vijverberg (ORCID: https://orcid.org/0000-0002-4579-4081)
- C Van Drunen
- Vojko Berce
- Boris Gole (ORCID: https://orcid.org/0000-0002-2461-6729)
- Gregor Jezernik (ORCID: https://orcid.org/0000-0003-1110-5345)
- Aaron Zee
- Susanne M. Reinartz
- Erik Melén
- Korneliusz Golebski
- Uroš Potočnik
Institutions
- University Hospital Regensburg (DE)
- University of Maribor (SI)
- Stockholm South General Hospital (SE)
- Emma Kinderziekenhuis (NL)
- Ambulance Care (Sweden) (SE)
- University Clinical Centre Maribor (SI)
- Tergooi (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3389/fimmu.2026.1744735
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- ZonMw
- Bundesministerium für Bildung und Forschung
- Karolinska Institutet
- Javna Agencija za Raziskovalno Dejavnost RS
- Vetenskapsrådet
- Univerzitetni Klinični Center Maribor
- European Regional Development Fund